FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically to an isolated FN3 domain that specifically binds to a human CD8A protein; it can be used in medicine. The isolated FN3 domain contains an amino acid sequence with SEQ ID NO: 40-269; it can be used for detecting CD8-expressing cells in a biological sample.
EFFECT: obtaining CD8A-binding domains of FN3 type.
17 cl, 19 dwg, 14 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES TO TAU AND THEIR USE | 2018 |
|
RU2787779C2 |
| AMATOXIN ANTIBODY-DRUG CONJUGATES AND USE THEREOF | 2020 |
|
RU2826004C2 |
| MULTIVALENT AND MULTI-SPECIFIC 41BB-BINDING FUSED PROTEINS | 2017 |
|
RU2789648C2 |
| MULTIVALENT AND MULTISPECIFIC HYBRID PROTEINS THAT BIND TO DR5 | 2016 |
|
RU2748620C2 |
| RECOMBINANT MODIFIED FIBROBLAST GROWTH FACTORS AND THEIR THERAPEUTIC USE | 2018 |
|
RU2811435C2 |
| NEONATAL Fc RECEPTOR BINDING AFFIMERS | 2020 |
|
RU2817008C1 |
| CHIMERIC ANTIGEN RECEPTORS TARGETING VARIANT III OF EPIDERMAL GROWTH FACTOR RECEPTOR | 2017 |
|
RU2751662C2 |
| THERAPEUTIC ANTI-CANCER NEOEPITOPE VACCINE | 2017 |
|
RU2782422C2 |
| POLYPEPTIDE COMPRISING ANTIGEN-BINDING DOMAIN AND TRANSPORT SEGMENT | 2018 |
|
RU2815452C2 |
| TREATMENT OF MALIGNANT NEOPLASM USING HUMANIZED CHIMERIC ANTIGEN RECEPTOR AGAINST BCMA | 2015 |
|
RU2751660C2 |
